Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.
The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 22, 24 | 0.18 Increased by +13.95 K% | 0.23 Decreased by -21.74% |
| Nov 1, 23 | 0.21 Increased by +625% | 0.23 Decreased by -8.7% |
| Jul 31, 23 | 0.29 Increased by +93.33% | 0.23 Increased by +26.09% |
| Apr 26, 23 | 0.27 Increased by +50% | 0.18 Increased by +50% |
| Feb 27, 23 | -0 Increased by +99.59% | -0.07 Increased by +98.14% |
| Oct 26, 22 | -0.04 Increased by +80% | -0.01 Decreased by -300% |
| Aug 3, 22 | 0.15 Increased by +114.29% | 0.11 Increased by +36.36% |
| Apr 27, 22 | 0.18 Increased by +100% | 0.17 Increased by +5.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 648.83 B Increased by +109.33 K% | 88.66 B Increased by +174.25 K% | Increased by +13.66% Increased by +59.33% |
| Dec 31, 23 | 646.21 M Increased by +20.22% | 20.38 M Increased by +8.28 K% | Increased by +3.15% Increased by +6.91 K% |
| Sep 30, 23 | 585.97 M Increased by +15.95% | 40.38 M Increased by +707.01% | Increased by +6.89% Increased by +623.49% |
| Jun 30, 23 | 594.6 M Increased by +11.39% | 56.04 M Increased by +102.57% | Increased by +9.42% Increased by +81.86% |
| Mar 31, 23 | 592.95 M Increased by +14.17% | 50.85 M Decreased by -57.9% | Increased by +8.58% Decreased by -63.13% |
| Dec 31, 22 | 537.54 M Increased by +19.5% | -249 K Increased by +99.57% | Decreased by -0.05% Increased by +99.64% |
| Sep 30, 22 | 505.34 M Increased by +23.63% | -6.65 M Increased by +81.77% | Decreased by -1.32% Increased by +85.26% |
| Jun 30, 22 | 533.8 M Increased by +6.4% | 27.66 M Increased by +113.77% | Increased by +5.18% Increased by +100.91% |